Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyMolina Vimizim Prior Auth Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentMolina HealthcarePolicy C7068-A

    Vimizim (elosulfase alfa) Coverage Criteria for MPS IVA

    Customize your policy alerts

    Sign up for Molina Healthcare Policy C7068-A alerts

    Get alerted when Policy C7068-A changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs Molina Healthcare coverage and prior authorization for Vimizim (elosulfase alfa) to treat mucopolysaccharidosis type IVA (MPS IVA, Morquio A syndrome), subject to benefit eligibility and required clinical documentation.

    Policy Summary
    PayerMolina Healthcare
    PolicyVimizim (elosulfase alfa) Coverage Criteria for MPS IVA
    Policy CodePolicy C7068-A
    Change TypeNo material clinical or coverage changes
    Effective DateSep 24, 2026
    Next Review DateJul 1, 2027
    Key ActionSubmit a baseline 6-minute walk test documenting that the member walked at least 30 meters in six minutes.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    MPS IVACovered indication
    Age 5+Minimum age
    30 metersBaseline walk requirement
    2 mg/kg weeklyDose limit
    12 months

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Authorization duration

    Coverage Criteria

    Initial Therapy Criteria

    Covered for initial therapy when all of the following are met:

    Required initial therapy criteria

    • Member has a documented diagnosis of mucopolysaccharidosis IVA (MPS IVA), also known as Morquio A syndrome.
    • Diagnosis is confirmed by reduced fibroblast or leukocyte GALNS enzyme activity, or by molecular genetic testing of GALNS.

      Documentation required.

    • Member has at least one qualifying symptom of MPS IVA, including kyphoscoliosis, genu valgum, pectus carinatum, gait disturbance, growth deficiency, short stature, spinal abnormalities, chest abnormalities, joint abnormalities, respiratory compromise, cardiac valve abnormalities, muscular weakness, visual impairment, hearing loss, or dental abnormalities and oral health challenges.At least one symptom
    • Baseline 6-minute walk test documents that the member walked at least 30 meters in six minutes.At least 30 meters in six minutes

      Documentation required.

    • Member is 5 years of age or older.5 years or older
    • Drug is prescribed by or in consultation with a board-certified geneticist, metabolic specialist, pediatric neurologist, pediatric developmentalist, endocrinologist, physician specializing in lysosomal storage disorders, or physician experienced in management of mucopolysaccharidoses.

      If prescribed in consultation, consultation notes are required with the initial and reauthorization requests.

    Continuation Therapy Criteria

    Continuation therapy is covered when all of the following are met:

    Required continuation therapy criteria

    • Prescriber attests to, or clinical reviewer finds, no evidence of intolerable adverse effects or drug toxicity, including anaphylaxis or severe allergic reactions.
    • Documentation demonstrates a positive clinical response to therapy from baseline, including stabilization or improvement in symptoms or the 6-minute walk test.

      Documentation required.

    Covered Indication

    The policy-supported use is treatment of Morquio A syndrome after diagnosis has been confirmed by an enzyme activity test.

    Vimizim-supported use

    • Use Vimizim (elosulfase alfa) to treat Morquio A syndrome, also known as mucopolysaccharidosis type IVA (MPS IVA).
    • Diagnosis is confirmed by an enzyme activity test.Diagnosis confirmed by enzyme activity test

      All other uses are considered experimental or investigational and follow Molina's Off-Label policy.

    All other uses of Vimizim (elosulfase alfa) are considered experimental or investigational and follow Molina’s Off-Label policy. Coverage under this policy is limited to the treatment of Morquio A syndrome (mucopolysaccharidosis type IVA) after diagnosis has been confirmed by an enzyme activity test.

    If a severe hypersensitivity reaction, including anaphylaxis, occurs, Vimizim must be discontinued and appropriate medical treatment initiated immediately, including epinephrine when indicated. Treatment should be administered in a healthcare setting with appropriate monitoring and access to cardiopulmonary resuscitation equipment.

    All other uses of Vimizim (elosulfase alfa) are considered experimental or investigational and follow Molina’s Off-Label policy. The covered use is treatment of Morquio A syndrome, or mucopolysaccharidosis type IVA, following confirmation of the diagnosis by an enzyme activity test.

    Coding and Clinical Parameters

    DiagnosisICD-10
    E76.210Morquio A mucopolysaccharidoses
    Covered HCPCS CodesHCPCSCovered
    J1322Injection, elosulfase alfa, 1 mg
    HCPCS CodeHCPCS
    J1322Injection, elosulfase alfa, 1 mg
    Baseline 6-Minute Walk Test
    RequirementBaseline 6-minute walk test (6-MWT)
    Minimum distanceAt least 30 meters in six minutes
    DocumentationThe baseline test must document the member’s walking distance
    Minimum Age
    Minimum age5 years of age and older
    Applies toMembers requesting Vimizim coverage
    Coverage stage

    Authorization and Documentation Requirements

    Prior Authorization

    Initial Authorization Requirements

    Before requesting initial authorization, submit documentation of MPS IVA (Morquio A syndrome), confirmatory GALNS testing, at least one qualifying disease manifestation, and the required baseline functional assessment.

    • Documented diagnosis of MPS IVA.
    • Reduced fibroblast or leukocyte GALNS enzyme activity or molecular genetic testing of GALNS.
    • At least one qualifying symptom or manifestation and a baseline 6-minute walk test showing at least 30 meters in six minutes.
    Prior Authorization

    Authorization Duration and Renewal

    Initial and continuation authorizations are each approved for 12 months. For renewal, submit the required attestation or clinical documentation supporting continued therapy.

    • Initial authorization: 12 months.
    • Continuation authorization: 12 months.

    Disease and Treatment Background

    MPS IVA, also called Morquio A syndrome, is a rare, progressive genetic lysosomal storage disorder caused by deficiency of N-acetylgalactosamine-6-sulfatase (GALNS). The deficiency results in keratan sulfate accumulation and may cause skeletal dysplasia, short stature, joint and spinal abnormalities, respiratory compromise, cardiac valve disease, hearing or visual impairment, and reduced mobility and endurance. Vimizim (elosulfase alfa) is a recombinant GALNS enzyme replacement therapy intended to address the underlying enzyme deficiency.

    Definitions

    MPS IVA
    Full nameMucopolysaccharidosis type IVA
    Also calledMPS IVA or Morquio A syndrome
    Underlying disorderA genetic lysosomal storage disorder caused by GALNS deficiency
    6-Minute Walk Test
    Test6-minute walk test (6-MWT)
    Policy useBaseline and response measure for walking endurance
    Initial eligibility thresholdAt least 30 meters in six minutes

    Initial Therapy

    Initial Therapy Criteria

    Initial therapy requires all of the following:

    Initial therapy requirements

    • Documented diagnosis of mucopolysaccharidosis IVA (MPS IVA, Morquio A syndrome).
    • Confirmatory testing

      • Diagnosis is confirmed by reduced fibroblast GALNS enzyme activity.
      • Diagnosis is confirmed by reduced leukocyte GALNS enzyme activity.
      • Diagnosis is confirmed by molecular genetic testing of GALNS.

    Continuation Therapy

    Continuation Therapy Criteria

    Continuation therapy requires both safety/tolerability and documented positive clinical response:

    Continuation therapy requirements

    • Prescriber attests to, or clinical reviewer finds, no evidence of intolerable adverse effects or drug toxicity, including anaphylaxis or severe allergic reactions.
    • Member demonstrates a positive clinical response to therapy from baseline, including stabilization or improvement in symptoms or the 6-minute walk test.

      Documentation required.

    Quantity and Dosing Limits

    Quantity Limit
    MedicationVimizim (elosulfase alfa)
    Quantity and dose limit2 mg/kg
    FrequencyOnce weekly

    Administration Site of Care

    Billing Rule

    Use an appropriate infusion-center setting

    Infused Vimizim is recommended for pharmacy or medical benefit coverage when administered in a non-hospital facility-based location under Molina's Site of Care program.

    • Apply the Molina Site of Care Utilization Management Policy for Vimizim.
    • Use a non-hospital facility-based place of service when applicable.
    Note

    Administer Vimizim with emergency support

    Initiate Vimizim in a healthcare setting with appropriate medical monitoring and support measures, including access to cardiopulmonary resuscitation equipment.

    • Monitor for severe hypersensitivity reactions, including anaphylaxis.
    Policy Summary
    PayerMolina Healthcare
    PolicyVimizim (elosulfase alfa) Coverage Criteria for MPS IVA
    Policy CodePolicy C7068-A
    Change TypeNo material clinical or coverage changes
    Effective DateSep 24, 2026
    Next Review DateJul 1, 2027
    Key ActionSubmit a baseline 6-minute walk test documenting that the member walked at least 30 meters in six minutes.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Clinical ParametersAuthorization and Documentation RequirementsDisease and Treatment BackgroundDefinitionsInitial TherapyContinuation TherapyQuantity and Dosing LimitsAdministration Site of Care
    Initial therapy eligibility
    Vimizim Dose
    MedicationVimizim (elosulfase alfa)
    Dose2 mg/kg
    FrequencyOnce weekly
    Diagnosis Confirmation
    RequirementDiagnosis confirmation before treatment initiation
    Confirmation methodEnzyme activity test
    Supported conditionMorquio A syndrome (mucopolysaccharidosis type IVA)
  1. Submit continuation documentation with each reauthorization request.
  2. Documentation Required

    Updated FDA Labeling Review

    If Vimizim receives an updated FDA label within the prior 180 days, Molina will review medical necessity using the updated labeling information. Coverage is determined case by case until Molina updates the criteria through clinical governance.

    • Review updated FDA label information issued within the last 180 days.
    • Additional information may be required for adequate review.
    Documentation Required

    General Supporting Records

    Submit complete medical rationale and supporting documentation with requests for Vimizim or exceptions to the guideline.

    • Records may include patient records, test results, and credentials of the ordering or performing provider.
    • When dosing is based on weight, body surface area, or another member-specific measurement, submit that measurement.
    Documentation Required

    Confirmatory GALNS Testing

    Confirm the MPS IVA diagnosis with documented reduced GALNS enzyme activity in fibroblasts or leukocytes, or with molecular genetic testing of GALNS.

    • The confirmatory testing documentation is required for authorization.
    Documentation Required

    Qualifying Disease Manifestations

    Document at least one qualifying MPS IVA symptom or manifestation.

    • Qualifying manifestations include kyphoscoliosis, genu valgum, pectus carinatum, gait disturbance, growth deficiency or short stature, spinal or chest abnormalities, joint abnormalities, respiratory compromise, cardiac valve abnormalities, muscular weakness, visual impairment, hearing loss, or dental abnormalities and oral health challenges.
    Documentation Required

    Baseline 6-Minute Walk Test

    Submit a baseline 6-minute walk test documenting that the member walked at least 30 meters in six minutes.

    • Baseline 6-MWT documentation is required.
    Prior Authorization

    Continuation Response and Safety

    For continuation therapy, document positive clinical response from baseline, including stabilization or improvement in symptoms or 6-minute walk performance, and confirm that treatment remains safe and tolerated.

    • Prescriber attestation or clinical review must find no intolerable adverse effects or drug toxicity.
    • Consider serious reactions including anaphylaxis and severe allergic reactions.
    Documentation Required

    Consultation Notes

    When Vimizim is prescribed by a physician in consultation with a qualified specialist, submit the consultation notes with both the initial request and each reauthorization request.

    • Qualified specialists include a board-certified geneticist, metabolic specialist, pediatric neurologist, pediatric developmentalist, endocrinologist, lysosomal storage disorder specialist, or physician experienced in managing mucopolysaccharidoses.
    Prior Authorization

    Diagnostic Confirmation

    Treatment should be initiated after the MPS IVA diagnosis has been confirmed by an enzyme activity test.

    • Confirm diagnosis by enzyme activity testing before treatment begins.
    Denial Risk

    Noncovered or Investigational Use

    Uses of Vimizim other than the supported MPS IVA indication are not covered under this guideline and must be evaluated under Molina's Off-Label policy.

    • All other uses are considered experimental or investigational.
    Denial Risk

    Insufficient Eligibility Documentation

    Molina may deny coverage when required eligibility evidence is missing or insufficient, including documentation of diagnosis, confirmatory testing, qualifying manifestations, baseline functional status, or other required clinical information.

    • Ensure all required medical information and documentation are submitted with the request.
    • Additional documentation may be requested on a case-by-case basis.
    Denial Risk

    Unsupported Medical Necessity or Billing

    Molina may deny reimbursement or take other appropriate action when the submitted documentation does not support medical necessity, non-investigational use, benefit eligibility, or the appropriateness of the billing or other practice.

    • Molina may act when documentation demonstrates inappropriate or excessive billing or other practice.
    Denial Risk

    Non-Supported or Off-Label Use

    Uses of Vimizim other than the supported indication are experimental or investigational and are subject to Molina's Off-Label policy.

    • Do not assume coverage for non-supported or off-label use.
    Billing Rule

    Billing or Benefit Exclusion

    Claims may be denied or payment may be recovered when services are improperly billed or are not covered under the member's benefit document.

    • Policy codes are for reference and do not guarantee coverage.
    • Use industry-standard coding practices; deleted or ineffective codes may not be eligible for reimbursement.
    • Coverage depends on benefit eligibility and the applicable benefit document.
    6-Minute Walk Test in the Pivotal Study
    Test6-minute walk test (6MWT)
    Study useEfficacy measure in the pivotal Vimizim study
    InterpretationResults depend on the individual member’s effort and motivation
    3-Minute Stair Climb Test
    Test3-minute stair climb test (3MSCT)
    Study useEfficacy measure in the pivotal Vimizim study
    InterpretationResults depend on the individual member’s effort and motivation
    Neutralizing Antibodies
    TermNAbs
    MeaningNeutralizing antibodies
    Clinical contextMay develop during treatment with the recombinant enzyme; Vimizim is also associated with infusion reactions
    At least one qualifying MPS IVA symptom is documented: kyphoscoliosis, genu valgum, pectus carinatum, gait disturbance, growth deficiency, short stature, spinal abnormalities, chest abnormalities, joint abnormalities, respiratory compromise, cardiac valve abnormalities, muscular weakness, visual impairment, hearing loss, or dental abnormalities and oral health challenges.At least one symptom
  3. Baseline 6-minute walk test documents that the member walked at least 30 meters in six minutes.At least 30 meters in six minutes

    Documentation required.

  4. Member is 5 years of age or older.5 years or older
  5. The drug is prescribed by or in consultation with a board-certified geneticist, metabolic specialist, pediatric neurologist, pediatric developmentalist, endocrinologist, physician specializing in lysosomal storage disorders, or physician experienced in management of mucopolysaccharidoses.

    If prescribed in consultation, consultation notes must be submitted with the initial request and reauthorization requests.

  6. Initial Therapy — Diagnostic Confirmation

    Treatment should be initiated after the diagnosis has been confirmed by an enzyme activity test.

    Initial Vimizim therapy

    • Initiate Vimizim (elosulfase alfa) for Morquio A syndrome, also known as mucopolysaccharidosis type IVA (MPS IVA).
    • Diagnosis has been confirmed by an enzyme activity test.Diagnosis confirmed by enzyme activity test

      Initiate Vimizim in a healthcare setting with appropriate medical monitoring and support measures, including access to cardiopulmonary resuscitation equipment.

  7. If a severe hypersensitivity reaction occurs, discontinue Vimizim and immediately initiate appropriate medical treatment, including epinephrine.